bevacizumab + ABT-510

Bevacizumab + ABT-510 is a combination therapy investigated for the treatment of advanced solid tumors. Bevacizumab is a monoclonal antibody that targets and neutralizes vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis, the process by which new blood vessels form to supply nutrients and oxygen to tumors[1][6]. ABT-510 is a synthetic peptide mimetic of thrombospondin-1 (TSP-1), an endogenous inhibitor of angiogenesis, and works by blocking multiple proangiogenic growth factors including vascular endothelial growth factor A (VEGF-A), bFGF, HGF, and IL-8[3][4]. The rationale for combining these agents is to achieve more complete inhibition of tumor angiogenesis by targeting both proangiogenic signals (via vascular endothelial growth factor A (VEGF-A) blockade) and enhancing antiangiogenic pathways (via TSP mimetic activity)[2][3]. This combination has been evaluated in phase I clinical trials in patients with refractory solid tumors, showing tolerability with some evidence of disease stabilization[2][3].

Other names

bevacizumabABT 510ABT510ABT-510